痰热清注射液治疗慢性阻塞性肺疾病急性加重期临床观察

Therapeutic Effect of Tanreqing in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: a Clinical Observation

目的评价痰热清注射液对慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效及安全性。方法128例中重度AECOPD患者按照随机对照试验研究设计随机分为治疗组和对照组各64例。两组均给予AECOPD常规治疗,治疗组并同时予痰热清注射液治疗。观察两组治疗前、治疗10 d后患者临床症状评分、肺功能、血气分析值,统计两组患者平均住院日,记录治疗期间不良反应发生情况。结果治疗10 d后,治疗组临床症状、肺功能、血气分析值较对照组明显改善(P<0.05),治疗组临床疗效优于对照组。观察至患者病情缓解、恢复到COPD稳定期水平时,治疗组平均住院日短于对照组(P<0.05)。两组治疗期间均未发生明显不良反应。结论对AECOPD患者,在常规治疗的基础上加用痰热清注射液可明显提高临床疗效,缩短平均住院日,安全可靠。

Objective: To evaluate the clinical curative effects and safety of Tanreqing injection in the treatment of acute exacerbations of chronic obstructive pulmonary disease(AECOPD). Methods: A total of 128 patients with moderate to severe AECOPD were randomly divided into the treatment group and the control group, according to the randomized controlled trial principle, each group had 64 cases. The conventional?treatment for AECOPD was given to both groups, and Tanreqing injection was given to the treatment group only. The clinical symptoms score, pulmonary function, and blood gas analysis of patients in two groups were measured before and ten days after treatment. The average hospitalization days in two groups were calculated. And the adverse reactions during treatment were also recorded. Results: The clinical symptoms, pulmonary function and blood gas analysis of the treatment group were significantly better than those in the control group after 10 days(P < 0.05). The average hospitalization days in the treatment group were significantly shorter than those in the control group(P <0.05), and the disparity was 2.1 days. No obvious adverse reactions occurred during the treatment in both groups.Conclusion: For AECOPD patients, on the basis of conventional?treatment, additional Tanreqing injection therapy can obviously improve the clinical curative effect and shorten the average hospitalization days. In addition,Tanreqing injection is safe and reliable.